Nearly 12% of Americans have used GLP-1 weight loss drugs
Nearly 12% of Americans have used GLP-1 drugs for weight loss, including about one-fifth of women aged 50 to 64, according to a new RAND report. Surveying a… read more.
Nearly 12% of Americans have used GLP-1 drugs for weight loss, including about one-fifth of women aged 50 to 64, according to a new RAND report. Surveying a… read more.
Pfizer Inc. announced that the FDA has approved the supplemental Biologics License Application (sBLA) for Adcetris (brentuximab vedotin) in combination with lenalidomide and a rituximab product for the… read more.
Of 1.7 million referrals for therapy in 2022-23, more than 1 million people dropped out before starting or during their therapy. This represents a dropout rate of over… read more.
Despite concerns about increased stimulant prescribing, nonmedical use of ADHD drugs among adolescents has declined in the last 20 years, a University of Michigan study shows. While medical… read more.
AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL)… read more.
Children and young adults who spend excessive hours glued to screens and electronic devices may have higher risks for cardiometabolic diseases, such as high blood pressure, high cholesterol… read more.
Bayer announced that the FDA has approved Jivi, a recombinant DNA-derived, extended half-life factor VIII concentrate, for use in pediatric patients 7 years of age and older with… read more.
Temporomandibular disorder (TMD) limits jaw function and is so painful that it lessens the quality of life. Botulinum toxin—also known as botox—is emerging as an effective treatment option,… read more.
McGill University researchers have developed and are licensing a digital tool to help safely reduce patients’ use of medications that may be unnecessary or even harmful to them…. read more.
Roche announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Columvi (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx) for… read more.
When performed prior to orthopaedic surgery, an evaluation from a health behavior psychologist can improve patient outcomes, according to a new study from the University of Missouri School… read more.
In a new study aimed at identifying the best approach to promote colorectal cancer screening in adults ages 45 to 49, UCLA researchers found that simply mailing a… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
